<div id="readability-page-1"><p>Cullen Frost Bankers Inc. raised its holdings in  GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 4.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375,481 shares of the pharmaceutical company's stock after purchasing an additional 16,999 shares during the period. Cullen Frost Bankers Inc.'s holdings in GSK were worth $14,418,000 at the end of the most recent quarter.</p><ul><li>Merck: 4 No-Brainer Reasons to Buy This Dip </li></ul><p>Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of  GSK in the fourth quarter worth approximately $528,000.  GAMMA Investing LLC boosted its stake in shares of  GSK by 107.8% in the first quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company's stock worth $172,000 after acquiring an additional 2,307 shares during the last quarter.  Wealth Enhancement Advisory Services LLC boosted its stake in shares of  GSK by 2.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 178,510 shares of the pharmaceutical company's stock worth $6,915,000 after acquiring an additional 3,822 shares during the last quarter.  Oppenheimer Asset Management Inc. boosted its stake in shares of  GSK by 20.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 140,106 shares of the pharmaceutical company's stock worth $5,428,000 after acquiring an additional 23,369 shares during the last quarter.  Finally, Aurora Private Wealth Inc. acquired a new stake in shares of  GSK in the first quarter worth approximately $692,000. 15.74% of the stock is owned by institutional investors and hedge funds. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages recently commented on GSK. Weiss Ratings  reiterated a &#34;hold (c)&#34; rating on shares of GSK in a research report on Wednesday, October 8th. Wall Street Zen upgraded GSK from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Friday, September 5th. Seven equities research analysts have rated the stock with a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat, GSK presently has an average rating of &#34;Reduce&#34; and an average target price of $37.38.</p><ul><li>After a Reset Year, Is Moderna Stock Poised for a Comeback?</li></ul><p><b>View Our Latest Report on GSK</b></p><h2>GSK Price Performance</h2><p>NYSE:GSK opened at $44.21 on Thursday. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $45.59. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $89.87 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.98 and a beta of 0.53. The stock's fifty day moving average is $41.31 and its two-hundred day moving average is $39.16. </p><ul><li>Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</li></ul><p>GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the previous year, the firm posted $0.43 earnings per share. The company's revenue was up 1.3% on a year-over-year basis.  GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts expect that  GSK PLC Sponsored ADR will post 4.14 EPS for the current year. </p><h2>GSK Cuts Dividend</h2><p>The business also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Friday, August 15th. GSK's payout ratio is presently 78.24%. </p><h2>GSK Profile</h2> (Free Report)<p>GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&amp;D.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than GSK</li><li>What is MarketRank™? How to Use it</li><li>Archer’s Recent String of Victories Signals a New Phase of Growth</li><li>How to Calculate Return on Investment (ROI)</li><li>3 Key Stocks Boosting Buybacks Amid Improving Fundamentals</li><li>What is the Nasdaq? Complete Overview with History</li><li>The Best AI for Picking Stocks, Ranked by Performance</li></ul><p><strong>Want to see what other hedge funds are holding GSK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GSK Right Now?</h2><p>Before you consider GSK, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.</p><p>While GSK currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GSK.WI

<p>Cullen Frost Bankers Inc. increased its holdings in GSK PLC Sponsored ADR by 4.7% in Q2, owning 375,481 shares valued at $14.4 million. Other institutional investors also adjusted their stakes. GSK's stock has a 52-week range of $31.72 to $45.59, with a current price of $44.21. The company reported Q2 earnings of $1.23 per share, exceeding estimates, and revenue of $10.64 billion. GSK recently announced a quarterly dividend of $0.4206 per share, yielding 3.8%.</p>

GSK PLC Sponsored ADR $GSK Shares Bought by Cullen Frost Bankers Inc.